Barriers and potential paths for biosimilars in the United States

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Jennifer Carioto, Harsha Mirchandani | 16 November 2018
With many expensive and innovative drugs in the pipeline and pressure from payers, legislators, and the Trump administration, strategies for lowering drug prices are becoming more prominent. Biosimilars can potentially reduce drug costs if barriers in the U.S. are removed or diminished.